Skip to main content

Table 3 Summary of results of the univariate analysis for treatment outcomes based on the candidate genotypes in the apoptosis pathway

From: Single nucleotide polymorphisms in apoptosis pathway are associated with response to imatinib therapy in chronic myeloid leukemia

Gene

SNP ID

Referent genotype

Adverse genotype

MCR

CCR

MMR

MR4.5

LOR

TF

PFS

OS

APAF1

rs1439123

CC/CT

TT

0.803

0.393

0.233

0.085

0.011*

0.323

0.510

0.939

APAF1

rs2288713

GG/TG

TT

0.747

0.886

0.617

0.530

0.812

0.992

0.271

0.863

CASP10

rs13006529

AA/TA

TT

0.250

0.433

0.513

0.671

0.144

0.025*

0.311

0.019*

FASLG

rs763110

TT/TC

CC

0.414

0.186

0.017*

0.123

0.145

0.097

0.001**

0.020*

FAS

rs1800682

TT/TC

CC

0.871

0.354

0.251

0.032*

0.086

0.129

0.428

0.863

FAS

rs2229521

GG/GA

AA

0.856

0.688

0.748

0.863

0.600

0.384

0.600

0.685

FAS

rs2234767

GG/GA

AA

0.944

0.259

0.179

0.013*

0.034*

0.093

0.374

0.978

FAS

rs2234978

TT/TC

CC

0.026*

0.036*

0.050*

0.011*

0.379

0.089

0.409

0.535

  1. SNP single nucleotide polymorphism, MCR major cytogenetic response, CCR complete cytogenetic response, MMR major molecular response, MR4.5 complete molecular response, LOR loss of response, TF treatment failure, PFS progression free survival, OS overall survival, APAF1 apoptotic peptidase activating factor 1, CASP10 caspase 10, FAS Fas cell surface death receptor, FASLG Fas ligand (TNF receptor superfamily member 6)
  2. ** p < 0.01/* p < 0.05